Serum free fatty acid biomarkers of lung cancer

Chest

Volumn 146, Issue 3, 2014, Pages 670-679

  Liu, Jinbo ^a,d   Mazzone, Peter J ^b   Cata, Juan P ^a,c,e   Kurz, Andrea ^a   Bauer, Maria ^a   Mascha, Edward J ^a,b   Sessler, Daniel I ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Allergy and Critical Care Medicine   (United States)

^c Department of Quantitative Health Sciences ^*  (United States)

^d CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 HYDROXYICOSATETRAENOIC ACID; 12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; FATTY ACID; HYDROXYICOSATETRAENOIC ACID; LINOLEIC ACID; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; HYDROXYOCTADECADIENOIC ACID; PHOSPHOLIPID; UNSATURATED FATTY ACID;

ADULT; AGE; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC DISEASE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FAMILY HISTORY; FATTY ACID BLOOD LEVEL; FEMALE; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SEX; SMOKING; SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; LUNG NEOPLASMS; MIDDLE AGED;

ADENOCARCINOMA; ADULT; AGED; AREA UNDER CURVE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FATTY ACIDS, NONESTERIFIED; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; LINOLEIC ACID; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; SENSITIVITY AND SPECIFICITY;

EID: 84907189040     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2568     Document Type: Article

References (53)

1. Oken MM, Hocking WG, Kvale PA, et al; PLCO Project Team. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA. 2011; 306 (17): 1865-1873.
2. Sox HC. Screening for lung cancer with chest radiographs. JAMA. 2011; 306 (17): 1916-1918.
3. Bach PB. Reduced lung-cancer mortality with CT screening. N Engl J Med. 2011; 365 (21): 2036.
4. Aberle DR, Adams AM, Berg CD, et al; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365 (5): 395-409.
5. Voelker DR, Lee TC, Snyder F. Fatty acid biosynthesis and dietary regulation in pulmonary adenomas. Arch Biochem Biophys. 1976; 176 (2): 753-756.
6. Kim HA, Kim KJ, Seo KH, Lee HK, Im SY. PTEN/MAPK pathways play a key role in platelet-activating factor-induced experimental pulmonary tumor metastasis. FEBS Lett. 2012; 586 (24): 4296-4302.
7. Kupert E, Anderson M, Liu Y, et al. Plasma secretory phospholipase A2-IIa as a potential biomarker for lung cancer in patients with solitary pulmonary nodules. BMC Cancer. 2011; 11: 513.
8. Zhang M, Xu ZG, Shi Z, et al. Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A 2 and peroxisome proliferator-activated receptor gamma. Mol Cell Biochem. 2011; 355 (1-2): 233-240.
9. Linkous AG, Yazlovitskaya EM, Hallahan DE. Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis. J Natl Cancer Inst. 2010; 102 (18): 1398-1412.
10. Granata F, Frattini A, Loff redo S, et al. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J Immunol. 2010; 184 (9): 5232-5241.
11. Ho JN, Lee SB, Lee SS, et al. Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol Cancer Ther. 2010; 9 (4): 825-832.
12. Weiser-Evans MC, Wang XQ, Amin J, et al. Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis. Cancer Res. 2009; 69 (5): 1733-1738.
13. Murakami M, Masuda S, Shimbara S, Ishikawa Y, Ishii T, Kudo I. Cellular distribution, post-translational modifi cation, and tumorigenic potential of human group III secreted phospholipase A(2). J Biol Chem. 2005; 280 (26): 24987-24998.
14. Murph M, Tanaka T, Pang J, et al. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 2007;433:1-25.
15. Gaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholineinduced migration of human breast cancer and melanoma cells. Mol Carcinog. 2009; 48 (9): 801-809.
16. Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer. 1997; 71 (1): 31-34.
17. Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2004; 13 (7): 1185-1191.
18. Zhou X, Mao J, Ai J, et al. Identifi cation of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics. PLoS ONE. 2012; 7 (11): e48889.
19. Guo Y, Wang X, Qiu L, et al. Probing gender-specific lipid metabolites and diagnostic biomarkers for lung cancer using Fourier transform ion cyclotron resonance mass spectrometry. Clin Chim Acta. 2012; 414: 135-141.
20. Connolly JM, Liu XH, Rose DP. Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice. Nutr Cancer. 1997; 29 (1): 48-54.
21. Rose DP, Connolly JM, Liu XH. Effects of linoleic acid on the growth and metastasis of two human breast cancer cell lines in nude mice and the invasive capacity of these cell lines in vitro. Cancer Res. 1994; 54 (24): 6557-6562.
22. Igal RA. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis. 2010; 31 (9): 1509-1515.
23. Hess D, Igal RA. Genistein downregulates de novo lipid synthesis and impairs cell proliferation in human lung cancer cells. Exp Biol Med (Maywood). 2011; 236 (6): 707-713.
24. Jeon SM, Chandel NS, Hay N. AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature. 2012; 485 (7400): 661-665.
25. Luo DX, Tong DJ, Rajput S, et al. Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential. Recent Patents Anticancer Drug Discov. 2012; 7 (2): 168-184.
26. Notarnicola M, Messa C, Caruso MG. A signifi cant role of lipogenic enzymes in colorectal cancer. Anticancer Res. 2012; 32 (7): 2585-2590.
27. Kerjaschki D, Bago-Horvath Z, Rudas M, et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenograft s in mouse. J Clin Invest. 2011; 121 (5): 2000-2012.
28. Moreno JJ. New aspects of the role of hydroxyeicosatetraenoic acids in cell growth and cancer development. Biochem Pharmacol. 2009; 77 (1): 1-10.
29. Wang D, DuBois RN. Measurement of eicosanoids in cancer tissues. Methods Enzymol 2007;433:27-50.
30. Paige M, Saprito MS, Bunyan DA, Shim YM. HPLC quantification of 5-hydroxyeicosatetraenoic acid in human lung cancer tissues. Biomed Chromatogr. 2009; 23 (8): 817-821.
31. Zick SM, Turgeon DK, Vareed SK, et al. Phase II study of the effects of ginger root extract on eicosanoids in colon mucosa in people at normal risk for colorectal cancer. Cancer Prev Res (Phila). 2011; 4 (11): 1929-1937.
32. Kudriavtsev IA, Miasishcheva NV. Synthesis of arachidonic acid cascade eicosanoids in tumors of various histogenesis in mice [in Russian]. Vestn Ross Akad Med Nauk. 1995;(4): 42-45.
33. Lockwood SF, Penn MS, Hazen SL, Bikádi Z, Zsila F. The effects of oral Cardax (disodium disuccinate astaxanthin) on multiple independent oxidative stress markers in a mouse peritoneal inflammation model: influence on 5-lipoxygenase in vitro and in vivo. Life Sci. 2006; 79 (2): 162-174.
34. Kelavkar UP, Glasgow W, Olson SJ, Foster BA, Shappell SB. Overexpression of 12/15-lipoxygenase, an ortholog of human 15-lipoxygenase-1, in the prostate tumors of TRAMP mice. Neoplasia. 2004; 6 (6): 821-830.
35. Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest. 1996; 97 (3): 806-813.
36. Ulbricht B, Henny H, Horstmann H, Spring H, Faigle W, Spiess E. Influence of 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE) on the localization of cathepsin B and cathepsin L in human lung tumor cells. Eur J Cell Biol. 1997; 74 (3): 294-301.
37. Chen YQ, Duniec ZM, Liu B, et al. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res. 1994; 54 (6): 1574-1579.
38. Honn KV, Nelson KK, Renaud C, Bazaz R, Diglio CA, Timar J. Fatty acid modulation of tumor cell adhesion to microvessel endothelium and experimental metastasis. Prostaglandins. 1992; 44 (5): 413-429.
39. Grossi IM, Fitzgerald LA, Umbarger LA, et al. Bidirectional control of membrane expression and/or activation of the tumor cell IRGpIIb/IIIa receptor and tumor cell adhesion by lipoxygenase products of arachidonic acid and linoleic acid. Cancer Res. 1989; 49 (4): 1029-1037.
40. Kudriavtsev IA, Miasishcheva NV, PolotskiѤ BE, Machaladze ZO, Davydov MI. Ability of the neoplastic tissue to biosynthesize 12-and 15-hydroxyeicosatetraenoic acids as criterion of metastasizing activity of human lung neoplasms [in Russian]. Biull Eksp Biol Med. 1998; 126 (9): 338-341.
41. Srivastava K, Kundumani-Sridharan V, Zhang B, Bajpai AK, Rao GN. 15(S)-hydroxyeicosatetraenoic acidinduced angiogenesis requires STAT3-dependent expression of VEGF. Cancer Res. 2007; 67 (9): 4328-4336.
42. Panigrahy D, Greene ER, Pozzi A, Wang DW, Zeldin DC. EET signaling in cancer. Cancer Metastasis Rev. 2011; 30 (3-4): 525-540.
43. Yuan H, Li MY, Ma LT, et al. 15-Lipoxygenases and its metabolites 15(S)-HETE and 13(S)-HODE in the development of non-small cell lung cancer. Thorax. 2010; 65 (4): 321-326.
44. Shureiqi I, Jiang W, Zuo X, et al. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid downregulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A. 2003; 100 (17): 9968-9973.
45. Bull AW, Branting C, Bronstein JC, Blackburn ML, Rafter J. Increases in 13-hydroxyoctadecadienoic acid dehydrogenase activity during differentiation of cultured cells. Carcinogenesis. 1993; 14 (11): 2239-2243.
46. Buchanan MR, Bertomeu MC, Haas TA, Gallo S, Eltringham-Smith L. Endothelial cell 13-HODE synthesis and tumor cell endothelial cell adhesion. Adv Prostaglandin Thromboxane Leukot Res. 1991; 21B: 909-912.
47. Nickkho-Amiry M, McVey R, Holland C. Peroxisome proliferator-activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma. Mol Cancer Res. 2012; 10 (3): 441-453.
48. Li H, Sorenson AL, Poczobutt J, et al. Activation of PPAR g in myeloid cells promotes lung cancer progression and metastasis. PLoS ONE. 2011; 6 (12): e28133.
49. van Eijsden M, van der Wal MF, Hornstra G, Bonsel GJ. Can whole-blood samples be stored over 24 hours without compromising stability of C-reactive protein, retinol, ferritin, folic acid, and fatty acids in epidemiologic research? Clin Chem. 2005; 51 (1): 230-232.
50. Salo MK, Gey F, Nikkari T. Stability of plasma fatty acids at -20 degrees C and its relationship to antioxidants. Int J Vitam Nutr Res. 1986; 56 (3): 231-239.
51. Rogiers V. Stability of the long chain non-esterified fatty acid pattern in plasma and blood during different storage conditions. Clin Chim Acta. 1978; 84 (1-2): 49-54.
52. Hirsch EZ, Slivka S, Gibbons AP. Stability of fatty acids in hyperlipoproteinemic plasma during long-term storage. Clin Chem. 1976; 22 (4): 445-448.
53. Matthan NR, Ip B, Resteghini N, Ausman LM, Lichtenstein AH. Longterm fatty acid stability in human serum cholesteryl ester, triglyceride, and phospholipid fractions. J Lipid Res. 2010; 51 (9): 2826-2832.